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IN OSTEOPOROTIC INDIVIDUALS
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introdUction
Osteoporosis is a common disease characterized 
by low bone mass and structural deterioration of 
the bone tissue, thus giving rise to diminished 
bone strength and increased susceptibility to 
fractures(1). At the menopause, the decrease in 
estrogen production leads to an imbalance in bone 
remodeling. Bone reabsorption occurs at a higher 
rate than bone formation does, which results in 
progressive bone loss and leads to postmenopausal 
osteoporosis and increased risk of fractures due to 
frailness(2). In postmenopausal women and in men 
aged 50 years or over, vertebral fractures may occur 
and may trigger chronic diseases and deformities, 
both in the hips and femoral head and in the spine, 
where such fractures are associated with increased 
morbidity and mortality, and a substantial economic 
impact(3). Therefore, clinical examinations for 
diagnosing and assessing the risk of fractures and 
for measuring bone mineral density are fundamental 
for following up this group of patients(4).
with dental procedures such as tooth extractions 
and other bone operations. In addition, tooth 
infections and periodontal disease have been 
reported to be the main risk factors for development 
of bisphosphonate-induced osteonecrosis of 
the maxillae. For this reason, dentists, general 
clinicians, orthopedists, geriatricians and oral-
maxillofacial surgeons need to be aware of 
this problem and work in a multidisciplinary 
environment, thereby stimulating early diagnosis 
and prevention of further potential cases. 
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aBstract
Bisphosphonate-related osteonecrosis of the 
maxillae may be an important complication of 
long-term osteoporosis treatment. The possibility 
of osteonecrosis of the maxillae in patients exposed 
to nitrogenated bisphosphonates was first described 
in 2003. Since then, case reports and retrospective 
studies have demonstrated higher percentages of 
occurrence of osteonecrosis in patients who have 
used or are using bisphosphonates. Although this 
complication may be spontaneous, invasive oral 
procedures have a role as risk factors associated 
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Bone metabolism is characterized by two simultaneous 
and opposite activities: bone deposition and reabsorption. 
During bone deposition, osteoblasts synthesize a matrix 
that undergoes primary mineralization followed by a 
long process of secondary mineralization. It is now 
known that osteoblastic differentiation is controlled 
by genes of the Hedgehog family (Indian Hedgehog 
and Sonic Hedgehog), transcription factor Cbfa-1 and 
bone morphogenetic proteins (BMPs), which are the 
most potent regulators of osteoblastic differentiation 
originating from undifferentiated mesenchymal cells(5). 
Bone reabsorption is performed by osteoclasts and 
consists of bone mineral dissolution and catabolism 
of the bone matrix components. Osteoclasts are 
large (100 μm) multinucleated cells that are rich 
in mitochondria and vacuoles containing tartrate-
resistant acid phosphatase, and which enable 
dephosphorylation of bone proteins. It is now 
known that the metabolism of osteoclastogenesis is 
dependent on osteoblasts and is regulated by three 
key molecules: osteoprotegerin (OPG), receptor 
activator of NF-kB ligand (RANKL) and receptor 
activator of NF-kB (RANK). RANKL is a member of 
the superfamily of tumor necrosis factors (TNF), and 
it is synthesized by osteoblasts, bone marrow stromal 
cells, T lymphocytes and endothelial cells. In binding 
to RANK (which is expressed in the precursors of 
osteoclasts, T lymphocytes and endothelial cells), 
the function of RANKL is to activate the osteoclasts, 
which leads to formation of multinucleated cells(6). 
In bone tissue, RANKL activity is increased and 
OPG activity is decreased through action by PTH, 
glucocorticoids and prostaglandin E2. On the other 
hand, the effects of RANKL are blocked by OPG, 
which acts as an antagonist receptor for RANKL, 
thereby preventing bone reabsorption(6). 
Therapeutic interventions that attenuate 
the risk of fractures are essential for reducing 
the consequences of this condition. Currently, 
the first-line treatment for osteoporosis is 
nitrogen-bearing bisphosphonates (BFs) such as 
alendronate, risedronate and ibandronate, which 
are agents for inhibiting bone reabsorption(7,8). BF 
medications are synthetic analogues of inorganic 
pyrophosphate: they are endogenous regulators 
of bone mineralization and have chelating action 
on calcium ions, thereby binding the ions to 
the hydroxyapatite of the bone surfaces that are 
undergoing remodeling. They potentially reduce the 
bone reabsorption rate because they inhibit mature 
osteoclasts and recruitment of their precursors. 
BFs are a class of medications that impede bone 
mass loss through inhibition of RANKL, which 
thus blocks the differentiation and activation of 
osteoclasts and consequently reduces pain and the 
risk of pathological fractures(6,9,10). 
In the literature, osteonecrosis induced by 
bisphosphonates (ONB) was initially addressed 
in 2003, by Migliorati(11), Marx(12), Wang et al(13) 
and Carter and Goss(14), who reported cases of 
patients with extensive osteolytic lesions similar 
to osteomyelitis in the maxillary bones. The origin 
of these lesions was attributed to therapy using high 
doses of BFs(15,16) (Figures 1, 2 and 3). Since then, case 
reports and retrospective studies have demonstrated 
occurrences of osteonecrosis of the maxillary bones, 
either with or without accompanying dentoalveolar 
surgical manipulation(17,18). Mechanisms involving 
microcirculation disorders, with the appearance of 
microthrombi that impede vascularization at the 
site, and involving inhibition of angiogenic factors 
such as the vascular angiogenic growth factor, 
have also been described(19). The modifications 
to vascularization that are inherent to ONB partly 
explain why the mandible is affected more than the 
maxilla is, given that the former has anatomically 
less vascularization than the latter does. The gnathic 
bones, and especially the mandible, would be the 
locations of choice for ONB because they are the 
only bones susceptible to constant microtraumas, 
because of the presence of the teeth, which stimulates 
constant bone turnover. In turn, the teeth are an 
entry point for pathogenic microorganisms along 
endodontic or periodontics routes, which facilitates 
establishment of infectious and inflammatory foci, 
for which repair is compromised by BFs(20-23).
Studies have indicated that bacterial infections 
have a role in ONB(23,24). Colonization by 
Actinomyces, Staphylococcus aureus  and 
Streptococcus sp(25) and by bacteria of the normal 
flora of the oral cavity(21) has been detected. In this 
respect, therapy with antibiotics is fundamental 
for disease control. Cofactors such as smoking, 
diabetes, use of steroids and other medications, 
anemia, hypoxia and kidney disorders(19) cannot 
be dismissed in the pathogenesis of ONB. 
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In 2009, the American Association of Oral and 
Maxillofacial Surgeons (AAOMS) established 
recommendations regarding the risk of developing 
ONB and its treatment. An expert committee 
defined ONB as persistent exposure of necrotic 
bone in the maxillofacial region, for more than eight 
weeks, in individuals without any history of previous 
radiotherapy in the neck region, who had used or were 
using bisphosphonates(19). From the scientific literature 
scrutinized up to that date, the AAOMS emphasized 
that the knowledge available on the relationship 
between bisphosphonates and necrosis of maxillary 
bones was based on retrospective studies limited to 
small samples, and on clinical case reports. From these 
studies, the AAOMS estimated that the incidence of 
ONB was between 0.8 and 12%, and affirmed that 
the risk of ONB among patients receiving intravenous 
bisphosphonates was significantly higher than among 
patients receiving them orally(19).
Ruggiero et al(21) established a clinical classification 
for lesions based on the levels of bone tissue destruction 
and the symptoms (Box 1). This has been widely used 
for prognosis and therapy in ONB cases. Regarding 
oral therapy, a systematic review showed that the 
prevalence of ONB was low (1/10,000 to 1/100,000 
patients/year)(26). In cases of therapy to control 
osteoporosis, this frequency was likewise low. A study 
demonstrated that out of 368 cases of ONB that were 
recorded, around 4% were in women who had used 
BF to treat or prevent osteoporosis(27). These estimates 
mostly involved cases treated using alendronate orally, 
and not using etidronate or ibandronate(28) (Box 2). 
Certain serum markers for predicting the risk 
of ONB among patients undergoing surgery on 
maxillary bones during their therapy with BFs have 
been suggested. Despite some controversy, and even 
though further studies are merited, telopeptide C of 
type I collagen (CTX) is considered to be an impor- 
Box 1 – Clinical classification of lesions according to the level of 
bone tissue destruction and symptoms(21).
clinical stage
0 – No clinical evidence of lesions, but with a risk of developing them.
1 – Exposure of necrotic bone tissue, but without symptoms.
2 – Exposure of symptomatic bone tissue, with or without secondary 
infection and suppuration.
3 – Widespread exposure of symptomatic bone tissue, with secondary 
infection, accompanied by some of the following items: pathological 
fracture, extraoral fistula or bone lysis extending to the lower edge 
of the mandible.
figure 1 – Panoramic radiograph showing extensive 
involvement of the mandible, with bone lesion in the right 
posterior portion.
figure 2 – Surgical specimen from mandible showing 
extensive ONB with pathological fracture.
figure 3 – Computed tomography image showing extensive 
mandibular bone destruction.
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tant marker for osteoclastic activity, and this may 
be indicated for monitoring the bone reabsorption 
levels under these conditions(29).
Oral rehabilitation among patients using oral BFs
The AAOMS recommends dental evaluation 
and complete rehabilitation before therapy with 
BFs is started. Dental preventive therapy is one of 
the factors shown to be effective for diminishing 
the risk of developing ONB, but it is incapable of 
eliminating the risk. Patients who are going to start 
treatment with BFs should present good oral health 
conditions. As part of the prior dental treatment, 
teeth that are no longer in a condition that can be 
restored should be eliminated. Invasive procedures 
(tooth extraction, implants, endodontic surgery and 
periodontal surgery) should be done at this time, 
and the mucosa at the intervention location needs to 
have healed (14-21 days) by the time of starting the 
therapy. Prophylaxis, caries control and restorative 
treatments should be implemented continually, 
and patients with total or partial prostheses should 
be assessed with regard to any presence of areas 
of trauma, especially in the lingual region of the 
mandible, since this is a region that is more liable 
to develop ONB(19). It is important to emphasize 
that patients who have made use of oral BFs for 
more than three years, especially when associated 
with another risk factor such as continual use of 
corticosteroids, present a greater risk of developing 
ONB and losing implants due to a higher long-term 
failure rate. Patients with osteoporosis who make 
use of oral BFs may benefit from the possibility 
of interruption of therapy three months before 
undergoing invasive procedures with installation 
of osseointegrated implants, and then restarting the 
therapy at least three months after the surgery, thus 
leading to lower risk of developing postoperative 
and ONB complications(19). 
We noted in the current literature that some 
studies aiming to evaluate implants installed in 
patients using oral BFs found failure rates similar 
to those of patients with normal reactions(30,31). 
However, at the same time, we noted an increasing 
number of clinical case reports on patients with long-
term use of oral BFs who underwent rehabilitation 
with implants and developed ONB. Thus, it is clear 
that the length of use of BFs is a crucial factor in 
planning and rehabilitation with implant-supported 
prostheses, such that patients who have used oral 
BFs for more than three years enter a category 
of increased risk of developing ONB and losing 
the implants. It is important to emphasize that the 
latest protocol published by the AAOMS(19) still 
places installation of osseointegrated implants in 
a high-risk category among oncological patients 
using intravenous BFs, thus contraindicating this 
procedure because of a lack of well-designed 
prospective studies with representative samples.
final remarks
Osteonecrosis of the maxillae induced by 
bisphosphonates has been recognized as an 
important complication from prolonged treatment 
for osteoporosis using such medications. The risk 
factors associated with dental procedures related 
to tooth extraction and other surgical procedures 
with bone involvement, as well as infections of 
dental and periodontal origins. Therefore, dentists, 
general clinical physicians, oral and maxillofacial 
surgeons and geriatricians should remain alert 
to this problem and work in a multidisciplinary 
manner to promote early diagnosis and prevention 
of potential new cases. Future research should 
aim towards acquiring information on safety and 
treatment options relating to ONB.
Box 2 – Bisphosphonate medications and their potency in 
relation to osteoporosis treatment.
generic name
commercial name/ 
administration 
route
manufacturer relative potency
Sodium 
alendronate 1,000
Fosamax/ oral Merck 500 – 1,000
Risedronate Actonel/ oral
Procter & 
Gamble
5,000
Ibandronate
Boniva/ oral/
intravenous
Roche 5,000 – 10,000
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